Sign in

CYTOF on OTC

Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. is a pharmaceutical preparations company based in Hamilton, Bermuda.2 Its shares trade on OTC under the symbol CYTOF.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$8.5MNet income, fiscal 20243

Compare with AC Immune SA or MindMaze Therapeutics Holding SA, or pick any stock.

  • TickerCYTOF on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersHamilton, Bermuda2
  • Incorporated inBermuda4
  • Business addressClarendon House, 2 Church Street, Hamilton Hm 11, D0 000004
  • Filer categoryNon-accelerated filer4
  • Legal formLimited2
  • LEI5299006WT2B254MR7Z422
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressClarendon House, 2 Church Street, HM 11 Hamilton, Bermuda2
  • Registered withRegistrar of Companies (Ministry of Economic Development), 545042

See how the biggest companies compare on our leaderboards

AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CHF, the currency the company reports in.

Key numbers, fiscal 2022

-372.4%Gross margin6
-6172.0%Operating margin3
-9089.3%Net margin3
378.4%Revenue growth, 20226

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue7¢1.4M CHF
  • Research and development72¢15.3M CHF
  • Selling, general and admin17¢3.6M CHF
  • Interest4¢934.0K CHF
  • Income tax0¢8.3K CHF

Out of 305.6K CHF in revenue.63 The company lost money this year.

Financial statements

Revenue6305.6K CHF in 2022+378% since 2021
0100.0K CHF200.0K CHF300.0K CHF400.0K CHF2021: 63.9K CHF63.9K CHF20212022: 305.6K CHF305.6K CHF2022+378%
Gross profit6-1.1M CHF in 2022−48% since 2021
-3.0M CHF-2.0M CHF-1.0M CHF02021: -2.2M CHF-2.2M CHF20212022: -1.1M CHF-1.1M CHF2022−48%
Net income73-27.8M CHF in 2022+142% since 2018
-30.0M CHF-20.0M CHF-10.0M CHF02018: -11.5M CHF-11.5M CHF20182019: -6.6M CHF-6.6M CHF2019−42%2020: -8.2M CHF-8.2M CHF2020+24%2022: -27.8M CHF-27.8M CHF2022+239%
Fiscal year201720182019202020212022
Revenue63.9K CHF6305.6K CHF6
Cost of revenue2.2M CHF61.4M CHF6
Gross profit-2.2M CHF6-1.1M CHF6
Research and development19.2M CHF86.7M CHF73.3M CHF72.9M CHF7$15.3M3
Selling, general and admin$3.6M3
Operating income-$18.9M3
Interest$934.0K3
Income before tax-$6.8M9-$19.5M3
Income tax$117.9K9-$8.3K3
Net income-11.5M CHF7-6.6M CHF7-8.2M CHF7-$27.8M3
Earnings per share-$610.033
Earnings per share (diluted)-$610.033
Shares (weighted, basic)33.1K shares945.5K shares3
Shares (weighted, diluted)662.3K shares6910.7K shares6

Compare Altamira Therapeutics Ltd. with another company

Corporate structure

Altamira Therapeutics Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Altamira Therapeutics Ltd.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Altamira Therapeutics Ltd., latest May 15, 2025 (3 filings since Nov 14, 2024)
  • Thomas Meyer Filed SCHEDULE 13D/A on Altamira Therapeutics Ltd., latest May 6, 2025 (6 filings since May 13, 2022)
  • Altamira Therapeutics Ltd. Hamilton, Bermuda

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Altamira Therapeutics Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$100.0K3 Dec 31, 2024$13 Dec 31, 2023+9999900.0%
Operating-lease assets (leased space)$349.9K3 Dec 31, 2024$95.2K3 Dec 31, 2023+267.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$998.6K3 Dec 31, 2024$733.7K3 Dec 31, 2023+36.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$4.6M3 Dec 31, 2024$4.6M3 Dec 31, 20230%

Former names

  • Auris Medical Holding Ltd.Feb 11, 2019 to Jul 23, 20214
  • Auris Medical Holding AGApr 15, 2014 to Mar 14, 20194
  • Auris Medical AGMar 18, 2014 to Apr 18, 20144

Timeline

  1. Mar 18, 2019Founded Altamira Therapeutics Ltd. is founded2

Filings

179 filings to the SEC since October 2021: 6 annual reports, 9 large holders, 164 other. The latest 20:

  1. Feb 27, 202615-12G FORM 15-12B EDGAR
  2. Aug 29, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Jun 17, 202525-NSE EDGAR
  4. Jun 11, 20256-K EDGAR
  5. May 15, 2025SCHEDULE 13G/A EDGAR
  6. May 9, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. May 6, 2025SCHEDULE 13D/A EDGAR
  8. Apr 30, 202520-F ANNUAL REPORT EDGAR
  9. Apr 30, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Apr 4, 2025S-8 REGISTRATION STATEMENT EDGAR
  11. Mar 10, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Feb 14, 2025SCHEDULE 13G/A EDGAR
  13. Dec 20, 20246-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Nov 14, 2024SC 13G EDGAR
  15. Oct 4, 20246-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Sep 24, 20246-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Sep 19, 20246-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Sep 18, 2024424B4 PROSPECTUS EDGAR
  19. Sep 17, 2024EFFECT EDGAR
  20. Sep 16, 2024CORRESP EDGAR

The 179 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 3 filings Nov 14, 2024 to May 15, 202513
  • Thomas MeyerSCHEDULE 13D/A, 6 filings May 13, 2022 to May 6, 202514

SEC filer profile

How Altamira Therapeutics Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAltamira Therapeutics Ltd.1
  • CIK0001601936
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inBermuda5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressClarendon House, 2 Church Street, Hamilton Hm 11, D0 000001
  • Phone41 (0) 41 729 71 941
  • Shares outstanding4,662,080 shares as of Dec 31, 20245
  • AuditorBDO AG, Zurich, Switzerland PCAOB ID 5988; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMar 18, 20141
  • Filings518 in all: 6-K (160), 424B3 (53), CORRESP (48), EFFECT (37), UPLOAD (28), SC 13D/A (21), F-1/A (20), F-1 (17)1
    All 41 form types

    SC 13G/A (14), 424B5 (12), POS AM (12), 20-F (11), SC 13G (11), 424B4 (9), F-3 (9), S-8 (8), FWP (7), SC 13D (5), POS EX (3), RW (3), 20-F/A (2), 25-NSE (2), 6-K/A (2), 8-A12B (2), 8-K12G3 (2), CERT (2), DRS/A (2), F-1MEF (2), SCHEDULE 13G/A (2), 15-12G (1), 15F-12B (1), 8-A12B/A (1), CERTNAS (1), CT ORDER (1), D (1), DRS (1), DRSLTR (1), F-4 (1), F-4/A (1), NT 20-F (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (20-F) Apr 30, 2025

Securities registered for trading

ClassSymbolExchange
Common Shares, par value $0.002 per shareCYTOFNONE

From the cover page of the 20-F filed Apr 30, 2025 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14